3K3A-APC
Alternative Names: 3K3A-activated protein C; 3K3A-APC non-anticoagulant mutant - ZZ Biotech; Activated-protein-C-analogue-University-of-Southern-California/Scripps-Research-Institute/ZZ-Biotech; Human-recombinant-3K3A-APC; Recombinant variant of human activated protein C (3K3A-APC)-ZZ-BiotechLatest Information Update: 11 Oct 2024
At a glance
- Originator Socratech; The Scripps Research Institute; University of Southern California
- Developer The Scripps Research Institute; University of Southern California; ZZ Biotech
- Class Anti-infectives; Anti-inflammatories; Antithrombotics; Blood proteins; Enzyme precursors; Foot disorder therapies; Recombinant proteins; Serine endopeptidases; Skin disorder therapies; Vascular disorder therapies
- Mechanism of Action Activated protein C receptor modulators; Factor V inhibitors; Factor VIII inhibitors; PAR 1 receptor modulators; PAR-3 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Amyotrophic lateral sclerosis; Ischaemic stroke
- Phase I Diabetic foot ulcer
- No development reported Stroke
- Discontinued Neurological disorders; Septic shock
Most Recent Events
- 11 Oct 2024 Discontinued - Preclinical for Neurological disorders in USA (IV), before October 2024 (ZZ Biotech Pipeline, October 2024)
- 11 Oct 2024 Discontinued - Preclinical for Septic shock in USA (IV), before October 2024 (ZZ Biotech Pipeline, October 2024)
- 01 Oct 2024 ZZ Biotech withdraws a phase III RHAPSODY-2 trial for Stroke (In adults, In the elderly) in USA (IV, Infusion), prior to enrolment due to NIH funding suspension (NCT05484154)